{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:19:54Z","timestamp":1785863994680,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcf.2024.07.015","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T17:47:24Z","timestamp":1722275244000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-6249","authenticated-orcid":false,"given":"Don B.","family":"Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-614X","authenticated-orcid":false,"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Polinieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-8004","authenticated-orcid":false,"given":"Elliott","family":"Dasenbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Szczesniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-0607","authenticated-orcid":false,"given":"Elizabeth A.","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.jcf.2024.07.015_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jcf.2024.07.015_bib0002","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1513\/AnnalsATS.201504-214OC","article-title":"Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Annals of the","volume":"12","author":"Sawicki","year":"2015","journal-title":"Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.015_bib0003","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcf.2024.07.015_bib0004","unstructured":"Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report. Bethesda, MD: 2023."},{"issue":"3","key":"10.1016\/j.jcf.2024.07.015_bib0005","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.015_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.07.015_bib0007","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jcf.2023.05.012","article-title":"Telehealth in Cystic Fibrosis. A systematic review incorporating a novel scoring system and expert weighting to identify a 'top 10 manuscripts' to inform future best practices implementation","volume":"22","author":"Vagg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.07.015_bib0008","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. Annals of the","volume":"13","author":"Knapp","year":"2016","journal-title":"American Thoracic Society"},{"issue":"6","key":"10.1016\/j.jcf.2024.07.015_bib0009","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2024.07.015_bib0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s41030-022-00202-y","article-title":"Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation","volume":"8","author":"Sawicki","year":"2022","journal-title":"Pulm Ther"},{"issue":"6","key":"10.1016\/j.jcf.2024.07.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jcf.2024.07.015_bib0012","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.07.015_bib0013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.pcl.2016.04.004","article-title":"Cystic Fibrosis Diagnosis and Newborn Screening","volume":"63","author":"Rosenfeld","year":"2016","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.015_bib0014","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ppul.26279","article-title":"Ren CL. Variation in cystic fibrosis newborn screening algorithms in the United States","volume":"58","author":"Rehani","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2024.07.015_bib0015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1164\/rccm.201001-0092OC","article-title":"Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis","volume":"182","author":"Nick","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.07.015_bib0016","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200403-404OC","article-title":"Late diagnosis defines a unique population of long-term survivors of cystic fibrosis","volume":"171","author":"Rodman","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.07.015_bib0017","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ppul.23715","article-title":"Risk factors for mortality before age 18 years in cystic fibrosis","volume":"52","author":"McColley","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.07.015_bib0018","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1378\/chest.14-2189","article-title":"Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California","volume":"149","author":"Buu","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.jcf.2024.07.015_bib0019","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1513\/AnnalsATS.201603-192BC","article-title":"Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis","volume":"13","author":"McGarry","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.07.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2022.2674","article-title":"Real-world Associations of US Cystic Fibrosis Newborn Screening Programs With Nutritional and Pulmonary Outcomes","author":"Rosenfeld","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.015_bib0021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:36:34Z","timestamp":1777332994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1569199324007999"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}